NASDAQ NMS - GLOBAL MARKET · CABA
+5.99% · +$0.1700 · Vol 6.5M
Cabaletta Bio Inc

Cabaletta Bio Inc

Biotechnology
$3.01

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is CABA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Cabaletta Bio Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2019
Employees
158
Country
US

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.99
Day high
$3.07
Day low
$2.91
Previous close
$2.84
52W high
$3.10
-2.90% from high
52W low
$2.82
68% of range
Market cap
$463.1M
EPS
$-2.2700
Shares out
163.1M
Volume
6.5M
VWAP
$3.00
Price history computed in-house
1W
+6.74%
SMA 50 $2.94 · above
SMA 200 $2.94 · above
52W position 68%
Veridion warehouse edge

Warehouse intelligence for CABA.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

CABA insider activity

Cabaletta Bio Inc

Score
Coverage building
Pressure
Net buying
Filings
8
Buys / sells
8 / 0
Net value
$296K
Insiders
8
Named filers
CJ
Chang David J.
Insider
Leadership
BG
Binder Gwendolyn
Insider
Leadership
GS
Gavel Steve
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net buying: $296K across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-01-212026-01-21Chang David J.Insiderbuy$2.268,8008,800$20KSEC Form 4
2026-01-212026-01-21Binder GwendolynInsiderbuy$2.1911,31231,312$25KSEC Form 4
2026-01-212026-01-21Gavel SteveInsiderbuy$2.2722,17022,170$50KSEC Form 4
2026-01-212026-01-21Bollard CatherineInsiderbuy$2.274,4055,405$10KSEC Form 4
2026-01-212026-01-21Gerard MichaelInsiderbuy$2.276,6006,600$15KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 3 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

CABA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CABA in this window.
Lobbying spend

CABA lobbying filings, year to date.

Registered lobbying filings matched to Cabaletta Bio Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CABA in this window.
Latest news · CABA
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for CABA.
Options
Sovereign unlock shows live options positioning for CABA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.